Cas9 Stable Cell Line - Panc 10.05

Pancreatic cancer represents a challenging malignancy with complex genetic landscapes characterized by numerous somatic mutations. The researchers demonstrated an innovative CRISPR-Cas9 strategy targeting specific somatic mutations with protospacer adjacent motifs (PAMs), enabling potentially selective cancer cell elimination. Their approach involved comprehensive whole genome sequencing, identifying multiple tumor-specific genomic targets, and developing a precise gene-editing mechanism capable of achieving 69-99% selective cell death in pancreatic cancer cell lines.

Figure 1. The researchers leveraged Panc10.05 and TS0111 cell lines to validate their CRISPR-Cas9 strategy, systematically testing multiple sgRNA targets to assess selective cancer cell killing efficiency and specificity through comprehensive genomic and cellular analyses. (Teh SSK, et al., 2024)

Creative Biogene's Panc 10.05 Cas9 Stable Cell Line offers researchers a robust platform for advanced cancer studies. Our meticulously developed cell line provides a reliable tool for investigating targeted gene editing strategies.